November 2017

 

 

academics

 

Clinical research courses

8 November 2017

Work as Medical Writing Specialist at Quintiles

Quintiles is the only fully integrated biopharmaceutical services company offering clinical, commercial, consulting and capital solutions worldwide. Our network of 23,000 engaged professionals in 60 countries around the globe works with an unwavering commitment to patients, safety and ethics — ensuring a higher level of healthcare for people. For our biopharmaceutical customers, we help them navigate risk and seize opportunities in an environment where change is constant.
Quintiles is consistently cited as the most favored contract research organization (CRO) in independent surveys of the bio pharma industry and was recently named “2009 CRO of the Year” by the prestigious SCRIP Awards.

Post : Medical Writing Documnt Spec 1-1721698

8 November 2017
A STUDY ON IDENTIFICATION OF RISK FACTORS IN DEVELOPING POLY CYSTIC OVARIAN SYNDROME AMONG TEENAGERS AND MINIMIZING THEM BY LIFE STYLE MODIFICATIONS THROUGH ADVANCED PATIENT COUNSELLING BY DOCTOR OF PHARMACY

{ DOWNLOAD AS PDF }

ABOUT AUTHORS
Dr. M. Manasa Rekha1*, Dr.M.Manasa2, C.Reddy Kumari2
1*,2 Doctor of pharmacy, Department of Pharmacy Practice,
Annamacharya college of Pharmacy,
Rajampet, Kadapa, Andhra Pradesh, India.
*manasarekharoyal@gmail.com

ABSTRACT:
Poly-Cystic Ovary Syndrome (PCOS) is characterized by multiple small ovarian cysts, obesity, hypertension, diabetes, insulin resistance, and Hirsutism. The Study Aims to assess the role of Doctor Of Pharmacy in identification of risk factors in developing poly cystic ovarian syndrome among teenagers and minimizing them by life style modifications through advanced Patient counseling.The Main Objective of the present study is to prevent the following: To prevent the complications of PCOS who are suffering with PCOS in early of their age. To prevent the occurrence of PCOS to early females who are nearer for its occurrence. To minimize the symptoms and to improve the quality of life of females suffering with PCOS. Study Design: It is a observational and interventional study. Study Period: The Present study was conducted for a period of 6 months from January 2nd  2017 to July 31st 2017.Study site : The Present study was conducted in BAHUDHA WOMENS HOSTEL affiliated to Annamacharya college of Pharmacy, Rajampet, Kadapa, Andhra Pradesh, India. In The Present Study Out of total 600 women   530 enrolled to participate in the present study. After the collection of information by PCOS  self assessment forms the scoring is given as 271 with scoring >5 with percentile 51.1320 are with Chance for getting PCOS, 159 with scoring > 10with percentile 30.01 are with high Chance for getting PCOS, 100 with scoring  <5with percentile 18.8679 are Unpredictable to PCOS. The present study concludes that Doctor Of Pharmacy is very helpful in assessing the risk factors responsible in developing PCOS and also minimizing them by life style modifications through advanced patient counseling.

Boehringer Ingelheim announced one-year data from VOLTAIRE®-RA, a pivotal Phase III clinical trial comparing Cyltezo® (adalimumab-adbm) and reference product Humira®*. The 48-week data showed that Cyltezo® is equivalent, with no clinically meaningful differences in efficacy, safety and immunogenicity to Humira® in people with moderately-to-severely active rheumatoid arthritis (RA), including in patients who switched from Humira® to Cyltezo® at week 24.

Takeda Pharmaceutical Company Limitedannounced that data from an 18-month interim analysis of the ongoing Phase 2 DEN-204 trial of its live, attenuated tetravalent dengue vaccine candidate, TAK-003 (also referred to as TDV), have been published in The Lancet Infectious Diseases. The results of this interim analysis, a pre-planned evaluation of data from an ongoing trial, show that TAK-003 is associated with a reduction in the incidence of dengue in children and adolescents. These data were also presented at the American Society of Tropical Medicine and Hygiene Annual Meeting. Phase 3 data are required to confirm these findings.

Cipla Ltd, a global pharmaceutical company which uses cutting-edge technology and innovation to meet the everyday needs of all patients, announced that its subsidiary, InvaGen Pharmaceuticals Inc. (collectively Cipla), has received final approval for its Abbreviated New Drug Application (ANDA) for Sevelamer Carbonate Tablets, 800 mg, from the United States Food and Drug Administration (USFDA) to market a generic version of Genzyme’s Renvela® Tablets, 800 mg.

Roche announced that the US Food and Drug Administration (FDA) has approved Zelboraf® (vemurafenib) for Erdheim-Chester disease (ECD) with BRAF V600 mutation. ECD is a rare, serious blood disease characterized by the abnormal multiplication of certain white blood cells called histiocytes, which can invade normal tissues and organs in the body.

(adsbygoogle = window.adsbygoogle || []).push({});
7 November 2017
Recruitment for Masters Degree in Life Sciences/Pharmacy at CDSA - Emoluments upto Rs. 75,000 pm | Government Jobs

Clinical Development Services Agency (CDSA) has therefore been formed as a not-for-profit society to provide supportive and focused environment to host world class clinical translation through a collaborative network of clinical investigators and premier research institutions.  It will tend enterprises, particularly SMEs involved in new technology innovation, to facilitate translation of scientific know-how into viable products for public health diseases like malaria, tuberculosis and dengue among others.

Post : Senior Research Officer (Zinc Sepsis Study)

7 November 2017
Career for M.Pharm, MS.Pharm, M.Sc in IIIM | Government Job

Indian Institute of Integrative Medicine (IIIM) is a national Institute of the Council of Scientific & Industrial Research (CSIR) of India, with primary focus of research on drug discovery from natural products (medicinal plants and microbial species). IIIM is a multi-disciplinary organization encompassing the natural products chemistry, medicinal chemistry, pharmacology, microbiology, biotechnology and botanical sciences.

Eligible & interested candidates are invited for WALK-IN-INTERVIEW for the following purely temporary positions of PROJECT ASSISTANT– II under the CSIR/ sponsored projects tenable at CSIR-IIIM, JAMMU:-

Subscribe with us




 


 

 

Do Not Forget to Verify

(Click on Subscription link in your inbox)

--------

whatsapp

 

Also Join:  youtube  telegram

Clini India

 

CLRI

Jobs by Category

Production Jobs

R&D Jobs

F&D Jobs

Sales & Marketing

QA Jobs

QC Jobs

Faculty Jobs

CRO Jobs

DRA Jobs

IPR Jobs

IT Jobs

Packaging Alerts

Hospital Pharmacist